Human Cell

, Volume 32, Issue 3, pp 352–359 | Cite as

MiR-1179 inhibits the proliferation of gastric cancer cells by targeting HMGB1

  • Yongsheng LiEmail author
  • Ce Qin
Research Article


Gastric cancer is one of the most common aggressive malignancies with high incidence and mortality. Increasing evidence has suggested that microRNAs (miRNAs) are involved in the initiation and development of gastric cancer. Here, we found that miR-1179 was significantly down-regulated in both gastric cancer tissues and cell lines. Decreased expression of miR-1179 was remarkably correlated with the increased tumor size, higher tumor stage and lymph node metastasis of gastric cancer patients. Overexpression of miR-1179 significantly inhibited the proliferation and invasion of gastric cancer cells. Further molecular experiments showed that miR-1179 bound the 3′-untranslated region of the high mobility group box 1 (HMGB1) and decreased the expression of HMGB1 in gastric cancer cells. The level of HMGB1 was negatively correlated with the expression of miR-1179 in gastric cancer tissues. Rescue experiment demonstrated that restore the expression of HMGB1 significantly inversed the inhibitory effect of miR-1179 on the proliferation of gastric cancer cells. Our results uncovered the novel function of miR-1179/HMGB1 axis in the progression of gastric cancer.


Gastric cancer MiR-1179 HMGB1 


Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflicts of interests.

Supplementary material

13577_2019_244_MOESM1_ESM.tif (1.5 mb)
Supplementary material 1 Supplementary Figure 1 Overexpression of miR-1179 decreased the expression of HMGB1 and inhibited the growth of MGC-803 and MKN-45 cells. a, b Overexpression of miR-1179 suppressed the proliferation of both MGC-803 and MKN-45 cells. c, d Transfection of miR-1179 inhibited the mRNA and protein expression of HMGB1 in MGC-803 and MKN-45 cells (TIF 1563 KB)


  1. 1.
    Zheng Y, Zhu XQ, Ren XG. Third-line chemotherapy in advanced gastric cancer: a systematic review and meta-analysis. Medicine (Baltimore). 2017;96(24):e6884. Scholar
  2. 2.
    Coburn N, Cosby R, Klein L, Knight G, Malthaner R, Mamazza J, et al. Staging and surgical approaches in gastric cancer: a systematic review. Cancer Treat Rev. 2018;63:104–15. Scholar
  3. 3.
    Shimizu D, Kanda M, Kodera Y. Review of recent molecular landscape knowledge of gastric cancer. Histol Histopathol. 2018;33(1):11–26. Scholar
  4. 4.
    Orditura M, Galizia G, Sforza V, Gambardella V, Fabozzi A, Laterza MM, et al. Treatment of gastric cancer. World J Gastroenterol. 2014;20(7):1635–49. Scholar
  5. 5.
    Song Z, Wu Y, Yang J, Yang D, Fang X. Progress in the treatment of advanced gastric cancer. Tumour Biol. 2017;39(7):1010428317714626. Scholar
  6. 6.
    Mohr AM, Mott JL. Overview of microRNA biology. Semin Liver Dis. 2015;35(1):3–11. Scholar
  7. 7.
    Fabian MR, Sonenberg N, Filipowicz W. Regulation of mRNA translation and stability by microRNAs. Annu Rev Biochem. 2010;79:351–79. Scholar
  8. 8.
    Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281–97.Google Scholar
  9. 9.
    Ambros V. The functions of animal microRNAs. Nature. 2004;431(7006):350–5. Scholar
  10. 10.
    Xie M, Ma L, Xu T, Pan Y, Wang Q, Wei Y, et al. Potential regulatory roles of microRNAs and long noncoding RNAs in anticancer therapies. Mol Ther Nucleic Acids. 2018;13:233–43. Scholar
  11. 11.
    Kwak PB, Iwasaki S, Tomari Y. The microRNA pathway and cancer. Cancer Sci. 2010;101(11):2309–15. Scholar
  12. 12.
    Farazi TA, Spitzer JI, Morozov P, Tuschl T. miRNAs in human cancer. J Pathol. 2011;223(2):102–15. Scholar
  13. 13.
    Qu H, Xu W, Huang Y, Yang S. Circulating miRNAs: promising biomarkers of human cancer. Asian Pac J Cancer Prev APJCP. 2011;12(5):1117–25.Google Scholar
  14. 14.
    Gentilin E, Degli Uberti E, Zatelli MC. Strategies to use microRNAs as therapeutic targets. Best Pract Res Clin Endocrinol Metab. 2016;30(5):629–39. Scholar
  15. 15.
    Yu H, Zhang J, Wen Q, Dai Y, Zhang W, Li F, et al. MicroRNA-6852 suppresses cell proliferation and invasion via targeting forkhead box J1 in gastric cancer. Exp Ther Med. 2018;16(4):3249–55. Scholar
  16. 16.
    Xu J, Wang F, Wang X, He Z, Zhu X. miRNA-543 promotes cell migration and invasion by targeting SPOP in gastric cancer. Onco Targets Ther. 2018;11:5075–82. Scholar
  17. 17.
    Park SK, Park YS, Ahn JY, Do EJ, Kim D, Kim JE, et al. MiR 21-5p as a predictor of recurrence in young gastric cancer patients. J Gastroenterol Hepatol. 2016;31(8):1429–35. Scholar
  18. 18.
    Kao HW, Pan CY, Lai CH, Wu CW, Fang WL, Huang KH, et al. Urine miR-21-5p as a potential non-invasive biomarker for gastric cancer. Oncotarget. 2017;8(34):56389–97. Scholar
  19. 19.
    Li Q, Li B, Li Q, Wei S, He Z, Huang X, et al. Exosomal miR-21-5p derived from gastric cancer promotes peritoneal metastasis via mesothelial-to-mesenchymal transition. Cell Death Dis. 2018;9(9):854. Scholar
  20. 20.
    Song L, Dai Z, Zhang S, Zhang H, Liu C, Ma X, et al. MicroRNA-1179 suppresses cell growth and invasion by targeting sperm-associated antigen 5-mediated Akt signaling in human non-small cell lung cancer. Biochem Biophys Res Commun. 2018;504(1):164–70. Scholar
  21. 21.
    Lin C, Hu Z, Yuan G, Su H, Zeng Y, Guo Z, et al. MicroRNA-1179 inhibits the proliferation, migration and invasion of human pancreatic cancer cells by targeting E2F5. Chemico-Biol Interact. 2018;291:65–71. Scholar
  22. 22.
    Xu X, Cai N, Zhi T, Bao Z, Wang D, Liu Y, et al. MicroRNA-1179 inhibits glioblastoma cell proliferation and cell cycle progression via directly targeting E2F transcription factor 5. Am J Cancer Res. 2017;7(8):1680–92.Google Scholar
  23. 23.
    Kumari T, Kumar B. High-mobility group box 1 protein (HMGB1) gene polymorphisms and cancer susceptibility: a comprehensive meta-analysis. Clin Chim Acta. 2018;483:170–82. Scholar
  24. 24.
    Huang CY, Chiang SF, Ke TW, Chen TW, Lan YC, You YS, et al. Cytosolic high-mobility group box protein 1 (HMGB1) and/or PD-1 + TILs in the tumor microenvironment may be contributing prognostic biomarkers for patients with locally advanced rectal cancer who have undergone neoadjuvant chemoradiotherapy. Cancer Immunol Immunother. 2018;67(4):551–62. Scholar
  25. 25.
    Xu Y, Chen Z, Zhang G, Xi Y, Sun R, Chai F, et al. HMGB1 overexpression correlates with poor prognosis in early-stage squamous cervical cancer. Tumour Biol. 2015;36(11):9039–47. Scholar
  26. 26.
    Wu T, Zhang W, Yang G, Li H, Chen Q, Song R, et al. HMGB1 overexpression as a prognostic factor for survival in cancer: a meta-analysis and systematic review. Oncotarget. 2016;7(31):50417–27. Scholar
  27. 27.
    Chen J, Li G. MiR-1284 enhances sensitivity of cervical cancer cells to cisplatin via downregulating HMGB1. Biomed Pharmacother. 2018;107:997–1003. Scholar
  28. 28.
    Lu L, Zhang D, Xu Y, Bai G, Lv Y, Liang J. miR-505 enhances doxorubicin-induced cytotoxicity in hepatocellular carcinoma through repressing the Akt pathway by directly targeting HMGB1. Biomed Pharmacother. 2018;104:613–21. Scholar
  29. 29.
    Tian L, Wang ZY, Hao J, Zhang XY. miR-505 acts as a tumor suppressor in gastric cancer progression through targeting HMGB1. J Cell Biochem. 2018. Scholar
  30. 30.
    Wu D, Liu J, Chen J, He H, Ma H, Lv X. MiR-449a suppresses tumor growth, migration and invasion in non-small cell lung cancer by targeting HMGB1-mediated NF-kappaB signaling way. Oncol Res. 2018. Scholar
  31. 31.
    Feng XJ, Liu SX, Wu C, Kang PP, Liu QJ, Hao J, et al. The PTEN/PI3K/Akt signaling pathway mediates HMGB1-induced cell proliferation by regulating the NF-kappaB/cyclin D1 pathway in mouse mesangial cells. Am J Physiol Cell Physiol. 2014;306(12):C1119-28. Scholar

Copyright information

© Japan Human Cell Society and Springer Japan KK, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Medical OncologyCangzhou Central HospitalCangzhouChina

Personalised recommendations